{
    "medicine_id": "ce95d4ad96d025b49be477b2c177d918ce41a68b",
    "platform_id": "DB04931",
    "metadata": {
        "name": "Scenesse 16 mg 16mg Implant",
        "composition": "16 mg 16mg Afamelanotide",
        "clinical_particulars": {
            "therapeutic_indications": "Afamelanotide is indicated for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria EPP L9086",
            "contraindications": {
                "disease": "Data regarding symptoms or treatment of afamelanotide overdose are currently unavailable L9086",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Afamelanotide increases the production of eumelanin an endogenous photoprotective agent to attenuate UV induced skin damage in patients with a condition that predisposes them to phototoxicity L9086 It has a relatively long duration of therapeutic effect despite its short half life due to its ability to increase melanosome density and therefore skin pigmentation A187202 As afamelanotide may darken pre existing skin pigmentary lesions patients receiving afamelanotide should undergo a full body skin examination every 6 months to monitor for progression or worsening of any skin abnormalities L9086 Standard sun safety measures should continue to be employed during afamelanotide therapy L9086",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}